8-K: Myomo Secures $17.5M Debt, Reports Q3 Losses Amid Revenue Growth

Myomo, Inc. announced a new $17.5 million debt facility and reported third-quarter 2025 financial results, showing revenue growth but increased net losses and a decline in gross margin.

Summary

• Myomo, Inc. entered into a Loan and Security Agreement with Avenue Capital Management II, L.P. for committed term loans up to $17.5 million, with $12.5 million funded on November 4, 2025.
• An additional $5.0 million (Tranche 2) is available between November 4, 2026, and May 4, 2027, and a discretionary Tranche 3 of up to $10.0 million may be funded between January 1, 2027, and December 31, 2027.
• The loans bear interest at an annual rate of 4.75% plus the Wall Street Journal prime rate (with a floor) and mature on June 1, 2029, with interest-only payments for 18 months (extendable to 24 months).
• The company issued a warrant to the lender to purchase up to $1,312,500 worth of common stock, with an exercise price of the lesser of $0.96 or the next equity financing price before June 30, 2026.
• Lenders have the right to convert up to $4.0 million of outstanding principal into common stock at 120% of the warrant exercise price, subject to ownership limitations.
• Third-quarter 2025 revenue was $10.1 million, a 10% increase compared to $9.2 million in Q3 2024, driven by a 16% increase in MyoPro units recognized (186 units).
• Gross profit for Q3 2025 decreased by 7% to $6.4 million from $6.9 million in Q3 2024, with gross margin declining to 63.8% from 75.4%.
• Operating expenses for Q3 2025 increased by 26% to $10.0 million from $7.9 million in Q3 2024.
• Net loss for Q3 2025 widened to $3.7 million, or $0.09 per share, compared to a net loss of $1.0 million, or $0.03 per share, in Q3 2024.
• Adjusted EBITDA for Q3 2025 was $(2.7) million, compared to $(0.6) million in Q3 2024.
• Cash, cash equivalents, and short-term investments were $12.6 million as of September 30, 2025, with $1.8 million cash used in operating activities during the quarter.
• The company reiterated its full-year 2025 revenue guidance of $40 million to $42 million, representing over 23% growth versus 2024.
• MyoPro orders in Q3 2025 were 229, the strongest quarter of the year, and 826 new candidates were added to the patient pipeline, with 1,669 patients in process.
• Marketing changes resulted in a 5% sequential decline in cost per pipeline add to $2,589.
• Manufacturing cost reduction projects are underway, expected to generate 200 basis points of gross margin improvement by Q3 2026.

Sentiment

Score: 4

Explanation: While Myomo achieved revenue growth and initiated promising strategic programs, the significant deterioration in gross margin and substantial increase in net and operating losses indicate worsening financial performance. The new debt facility provides necessary liquidity but introduces new financial covenants and potential dilution, reflecting a mixed but overall challenging financial picture.

Positives

• Revenue for Q3 2025 increased by 10% year-over-year to $10.1 million, and year-to-date revenue grew 44% to $29.6 million.
• International and U.S. orthotics and prosthetics (O&P) revenues reached record levels in Q3 2025.
• MyoPro orders in Q3 2025 totaled 229 units, marking the strongest quarter of the year for orders.
• Revenue velocity increased, with intra-quarter orders representing 57% of revenue units.
• The patient pipeline grew with 826 new candidates added, and a record 1,669 patients are currently in the process of obtaining a MyoPro.
• Marketing adjustments led to a 5% sequential decline in cost per pipeline add.
• The new MyoConnect program aims to strengthen relationships with therapists and physicians, expected to generate recurring patient referrals and improve pipeline quality.
• Secured a new Loan and Security Agreement providing up to $17.5 million in committed term loans, with $12.5 million funded at closing, enhancing liquidity.
• The new debt facility includes an initial 18-month interest-only payment period, extendable to 24 months, providing financial flexibility.

Negatives

• Gross profit for Q3 2025 decreased by 7% year-over-year to $6.4 million.
• Gross margin significantly declined to 63.8% in Q3 2025 from 75.4% in Q3 2024, primarily due to lower average selling price (ASP), higher material, payroll, and lease costs, and unfavorable overhead absorption.
• Operating expenses increased by 26% year-over-year to $10.0 million in Q3 2025, driven by higher advertising spending and increased R&D investments.
• Operating loss widened to $3.5 million in Q3 2025 from $1.0 million in Q3 2024.
• Net loss increased substantially to $3.7 million in Q3 2025 from $1.0 million in Q3 2024.
• Adjusted EBITDA worsened to $(2.7) million in Q3 2025 from $(0.6) million in Q3 2024.
• Cash used in operating activities increased to $1.8 million in Q3 2025 from $1.5 million in Q3 2024.
• The average selling price (ASP) for MyoPro units was approximately $54,200, down 5% compared to the prior year, which was atypically high.

Risks

• Ability to obtain sufficient reimbursement from third-party payers for products.
• Dependence on external sources for the financing of operations.
• Ability to scale the business to achieve positive cash flow from operations.
• Revenue concentration with patients who carry Medicare Part B.
• Ability to continue normal operations and patient interactions without supply chain disruption.
• Ability to maintain and grow strategic collaborations and realize intended results.
• Ability to remediate any material weakness in internal control over financial reporting.
• Expectations as to product development programs, including improving existing products and developing new ones.
• Ability to maintain and grow reputation and achieve and maintain market acceptance of products.
• Expectations as to clinical research program and clinical results.
• Ability to maintain adequate protection of intellectual property and avoid violation of others' intellectual property rights.
• Ability to gain and maintain regulatory approvals.
• Ability to compete and succeed in a highly competitive and evolving industry.
• General market, economic, environmental, and social factors that may affect product evaluation, fitting, delivery, and sale.
• Compliance with financial covenants in the Loan Agreement, including maintaining $2.5 million in unrestricted cash, achieving at least 75% of trailing three-month projected revenue, and managing cash burn.
• The Loan is secured by a senior lien on all company assets, including intellectual property, which could impact other creditors.
• Lender's right to convert up to $4.0 million of outstanding principal into common stock, potentially leading to dilution.
• Prepayment fees of 3.0%, 2.0%, or 1.0% of the principal amount outstanding depending on the timing of prepayment.

Future Outlook

Myomo expects full-year 2025 revenue to be within its previous guidance range of $40 million to $42 million, representing an increase of over 23% compared to 2024. The company anticipates its new MyoConnect program will generate recurring patient referrals, reduce the cost per pipeline add, and improve pipeline quality. Manufacturing cost reduction projects are expected to yield 200 basis points of gross margin improvement, fully realized starting in the third quarter of 2026.

Management Comments

• Paul R. Gudonis, Myomo's Chairman and CEO, stated, "Third quarter revenues were at the high end of our expectations, with International and U.S. orthotics and prosthetics ('O&P') revenues at record levels. Revenue increased while operating expenses decreased on a sequential basis, reflecting our focus on improving operating leverage."
• Gudonis added, "We also achieved our strongest quarter of the year for authorizations and orders, while the marketing changes we implemented during the quarter contributed to a sequential decline in cost per pipeline add of 5%."
• Gudonis further commented, "We believe the key to lowering cost per pipeline add is strengthening relationships with the therapists and physicians that are integrated into the continuum of care our patients receive, while reducing our reliance on advertising for lead generation. Under this new program, called MyoConnect, which is expected to generate recurring patient referrals, our clinical team engages with therapists and physicians nationwide to expand the network of healthcare professionals who understand the benefits of the MyoPro. We view MyoConnect as a more scalable means of growing our patient pipeline, while reducing cost per pipeline add and improving pipeline quality, and we are encouraged by the early results."
• Gudonis also noted, "We are also seeing growth from the O&P channel as more clinicians add the MyoPro to their product offerings and begin building their own patient pipelines."
• Regarding the outlook, Gudonis said, "We expect full year 2025 revenue within our previous guidance range of $40 million to $42 million, which represents an increase of more than 23% versus 2024."

Industry Context

Myomo operates in the wearable medical robotics industry, focusing on devices that restore upper-limb function for individuals with neurological disorders and paralysis. The company's MyoPro product line is positioned as a unique solution utilizing EMG signals. The strategic shift towards the MyoConnect program and O&P channel growth reflects an industry trend towards more integrated care pathways and diversified lead generation beyond traditional advertising, potentially enhancing scalability and cost-effectiveness in a competitive and evolving market for medical devices.

Corporate Governance

Stakeholder Impact

• Shareholders face potential dilution from the warrant exercise and debt conversion rights granted to the lender, as well as from future equity financings where the lender has a participation right. The new debt facility provides liquidity but also introduces significant financial covenants and a senior secured lien on all company assets, increasing financial risk.
• Employees are likely to see continued operations and product development, supported by the new financing.
• Customers (patients) should continue to have access to MyoPro products and services, with potential improvements in patient referral pathways through the MyoConnect program.
• Creditors, particularly existing unsecured creditors, may find their claims subordinated to the new senior secured debt held by Avenue Capital, increasing their risk exposure.

Next Steps

• Continue to implement the MyoConnect program to strengthen relationships with therapists and physicians for recurring patient referrals.
• Proceed with manufacturing cost reduction projects, aiming for 200 basis points of gross margin improvement by Q3 2026.
• Potentially draw down the $5.0 million Tranche 2 loan between November 2026 and May 2027, subject to conditions.
• Explore the possibility of securing the additional $10.0 million Discretionary Tranche 3 loan between January 2027 and December 2027.
• Hold a conference call on November 10, 2025, to discuss the Q3 2025 financial and operating results.

Key Dates

Recommendation

Myomo's Q3 2025 results present a mixed picture. While revenue growth and strategic initiatives like MyoConnect are positive, the significant decline in gross margin and widening net losses are concerning. The new $17.5 million debt facility provides crucial liquidity and runway, but it comes with stringent financial covenants, a senior secured lien on all assets, and potential future dilution from warrants and debt conversion rights. The company's ability to execute on its cost reduction projects and successfully scale its new patient acquisition strategies will be critical. Given the substantial financial challenges alongside promising strategic shifts and new financing, a 'hold' recommendation is appropriate. Investors should monitor the company's progress on gross margin improvement, cash burn reduction, and the effectiveness of its MyoConnect program before making further investment decisions.

Keywords

Wearable Medical Robotics, Neurological Disorders, Upper-Limb Paralysis, MyoPro, SEC Filing, 8-K, Debt Financing, Q3 Earnings, Revenue Growth, Net Loss, Gross Margin, Operating Expenses, Adjusted EBITDA, Patient Pipeline, MyoConnect, Orthotics and Prosthetics, Corporate Governance, Warrant, Convertible Debt